John Niederhuber - Aug 3, 2016 Form 4 Insider Report for Aptevo Therapeutics Inc. (APVO)

Role
Director
Signature
SoYoung Kwon, Attorney-in-Fact
Stock symbol
APVO
Transactions as of
Aug 3, 2016
Transactions value $
$650
Form type
4
Date filed
6/3/2022, 03:06 PM
Next filing
Jun 2, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APVO Common Stock Purchase $650 +714 +89.03% $0.91* 1.52K Jun 14, 2019 Direct F2
transaction APVO Common Stock Options Exercise +298 +19.66% 1.81K Jun 1, 2022 Direct F3
holding APVO Common Stock 802 Aug 3, 2016 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APVO Restricted Stock Unit Options Exercise $0 -298 -33.37% $0.00 595 Jun 1, 2022 Common Stock 298 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares received in a pro rata distribution by Emergent BioSolutions Inc. ("Emergent") as a result of the spin-off of the Issuer from Emergent, effective August 1, 2016, and adjusted to reflect a 1-for-14 reverse stock split of the Issuer's common stock effective as of March 26, 2020.
F2 Reflects a 1-for-14 reverse stock split of the Issuer's common stock effective as of March 26, 2020.
F3 Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.
F4 On June 1, 2021, the reporting person was granted 893 RSUs, vesting in three approximately equal annual installments beginning on June 1, 2022.